Edward Kaye 1,2, Kie Honjo 3,4, Ana Petrovic-Poljak 5, Robert van Reekum 6, David Streiner 1,6,7,8,9, Alan Wilson 6,10, Sandra Black 3,4,11, Morris Freedman.

Slides:



Advertisements
Similar presentations
Cerebral Glucose Metabolism in Obsessive-Compulsive Hoarding
Advertisements

DEPRESSION IN ELDERLY CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE: WHAT DOES IT DEPEND ON? Department of Alzheimer's disease and related disorders.
Cholinergic Dysfunction after Traumatic Brain Injury – A PET Study Anna Östberg 1, Jere Virta 2, Juha Rinne 2, Vesa Oikonen 2, Pauliina Luoto 2, Olli Tenovuo*
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.
Alzheimer’s Disease Edwin Onattu P. 3.
Variability of PET-PIB retention measurements due to different scanner performance in multi-site trials Jean-Claude Rwigema Chet Mathis Charles Laymon.
The Dependence of the Apparent Diffusion Coefficient on Voxel Location and Calculation Method Lars Ewell 1, Naren Vijayakumar Meeting of the American.
MCB 135K: Discussion March 2, General Info Mid-Term I: –Avg 87 –Std. Deviation 10 –Re-grades by next Wednesday Include a cover sheet that addresses.
2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt All about the Neuron The.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
There are currently 26 million people worldwide with Alzheimer’s disease. This figure is projected to grow to more than 106 million people by 2050.
CHAPTER TWO CHAPTER TWO Neuroscience as a Basis for Adult Development and Aging.
Modulation pharmacoMRI to investigate the neural effects of SSRIs on emotional face processing A. E. ÉDES 1,2, D. KOVÁCS 1,2, D. PAP 1,2, X. GONDA 1,2,3,
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
A New Method for Mapping the Linkage between Abnormal Gray Matter Loss and the Clinical and Cognitive Deficits in Childhood-Onset Schizophrenia 1 Christine.
James B. Brewer, Zuo Zhao, John D Desmond, Gary H. Glover, John D. E. Gabrieli Thomas Pierce.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Brain PET Scans in Patients with Minimal Pain Departments of Anesthesiology, Radiology, and Neurology Rush University Medical Center Rush Medical College.
Alzheimer’s Disease. Alzheimer's is a the most common form of dementia. Nearly 50-80% of all dementia patients have Alzheimer's. It is a progressive fatal.
 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer’s is the most common form of dementia. This.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part C – AD brain scans - anatomical NUCLEAR MEDICINE GRAND.
BRAIN IMAGING - PERSPECTIVES FOR STUDIES OF PSYCHIATRIC DISORDERS Jair C. Soares, M.D. Division of Mood and Anxiety Disorders, Dept of Psychiatry, University.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.
National Institute on Aging
Haga clic para modificar el estilo de subtítulo del patrón White matter microstructure disruption is correlated with amyloid burden in subjects with subjective.
 a type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly and get worse over time, becoming severe.
2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt All about the Neuron The.
High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.
White Matter Structural Integrity in Healthy Aging Adults and Patients With Alzheimer Disease: A Magnetic Resonance Imaging Study Bartzokis, et al. UCLA.
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Mechanism of Amyloid Removal in Patients With Alzheimer.
Positron Emission Tomography.
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: In Vivo Brain Concentrations of N-Acetyl Compounds,
Norton-scientificcollection.com/collection. HEALTH NEWS Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Plasma Clusterin Concentration With.
Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Meta-analysis of Functional Magnetic Resonance Imaging.
Alzheimer's Disease Biological LOA.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: In Vivo Fibrillar β-Amyloid Detected Using [11C]PiB.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Copyright © 2013 American Medical Association. All rights reserved.
Rosa Maria Moresco University of Milan Bicocca
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease  Azadeh Karami, Helga Eyjolfsdottir, Swetha.
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology 18Fluorine Sodium Fluoride Positron Emission Tomography,
Volume 21, Issue 4, Pages xv-xxiii (December 1998)
Imaging AD Progression Amyloid Imaging Agents.
Brain Tech TIME Case Study: FDG PET IMAGING IN DEMENTIA (FTD vs AD)
Keith A. Josephs, MD, MST, MSc  Mayo Clinic Proceedings 
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
All about the Neuron The Mighty Brain Neurological Disorders
Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.
Alan N. Hampton, Ralph Adolphs, J. Michael Tyszka, John P. O'Doherty 
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
Left middle frontal cortex, caudate nuclei
Network hubs in the human brain
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.
Advances in the War on Alzheimer's
Biomarker Modeling of Alzheimer’s Disease
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Patient 2- Alzheimer’s Disease
[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β.
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study  Osama Sabri, Marwan N. Sabbagh, John Seibyl, Henryk Barthel,
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Detecting and Diagnosing Alzheimer’s Disease
Presentation transcript:

Edward Kaye 1,2, Kie Honjo 3,4, Ana Petrovic-Poljak 5, Robert van Reekum 6, David Streiner 1,6,7,8,9, Alan Wilson 6,10, Sandra Black 3,4,11, Morris Freedman 4,11,12,13, Pablo Rusjan 10, Sylvain Houle 10, Paul Verhoeff 1,6,12,14 1 Kunin-Lunenfeld Applied Research Unit, Baycrest; 2 Institute of Medical Science, University of Toronto; 3 Division of Neurology, Sunnybrook Health Sciences Centre; 4 Division of Neurology, University of Toronto; 5 Mood Clinic, Baycrest; 6 Department of Psychiatry, University of Toronto; 7 Department of Psychiatry and Neuroscience, McMaster University; 8 McMaster Child Health Research Institute; 9 Health Systems Research and Consultation Unit, CAMH; 10 PET Centre, CAMH; 11 Rotman Research Institute, Baycrest; 12 Memory Clinic, Baycrest; 13 Division of Neurology, Baycrest; 14 Department of Psychiatry, Baycrest Introduction 1) Apathy correlates with amyloid plaque burden in the cingulate cortex, dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OFC). 2) Depression/dysphoria correlates with amyloid plaque burden in the medial temporal lobe (MTL), DLPFC, OFC. 3) Agitation/aggression correlates with amyloid plaque burden in the DLPFC, anterior cingulate cortex, temporal cortex. Alzheimer’s disease (AD) is the most common form of dementia. >80% of AD patients display at least one neuropsychiatric symptom (mood, psychotic, or behavioural). A primary pathology in AD is the presence of beta-amyloid, which accumulates into extraneuronal plaques. These plaques may be imaged with the radiolabeled tracer [ 11 C]SB-13. Question: Do patients with greater disturbances in particular neuropsychiatric symptoms also have greater amyloid plaque burden in particular brain regions? Hypotheses Methods Do Amyloid Plaques Correlate with Behavioural Symptoms in Alzheimer’s Disease? 10 mild AD patients (age years; MMSE scores, ) underwent 2 separate scans: 1. Magnetic Resonance Imaging (MRI) scan. 2. Positron Emission Tomography (PET) scan following injection of about 10 mCi of [ 11 C]SB-13. Administered the Neuropsychiatric Inventory (NPI) to an informed caregiver to assess 12 behavioural disturbances. Employed a semi-automatic brain extraction method to trace brain regions of interest (ROIs) on the T1-weighted MRI images, manually traced cerebellar grey matter. Coregistered MRI data with PET data (used AIR, FSL). Estimated regional amyloid plaque with the Standardized Uptake Value (SUV) for each ROI, calculated by normalizing tissue concentration (nCi/mL) by injected dose per body mass (nCi/g). Ratios of region of interest over cerebellum (the reference region) were also calculated (SUVRs). Both estimates were derived from the minute interval post-injection of the tracer [ 11 C]SB-13. Calculated correlations between NPI scores and regional SUVs and SUVRs using Pearson’s r, alpha=0.05. Results Table 2. Pearson correlation coefficients between mean total NPI score and regional SUVs. This project was supported by: Alzheimer’s Association Finkler Graduate Student Fellowship Harry C. Sharpe Fellowship Scace Graduate Fellowship for Research in Alzheimer’s University of Toronto Institute of Medical Science Fellowship Acknowledgments Apathy, depression/dysphoria, irritability/lability, and agitation/aggression were some of the behaviours present in most of our sample (Figure 1), as expected for the mild AD population, and caused the greatest disturbance (Table 1). Figure 2 depicts a MRI image with regions of interest traced (left) and coregistered with its corresponding PET image (right). Figure 3 depicts uptake of [ 11 C]SB-13 in the brain indicating location and density of amyloid plaques. Table 2 shows that SUVs in the left MTL correlate with depression/dysphoria, and that SUVs in bilateral temporal cortex, DLPFC, and ACC correlate with agitation/aggression. There were no significant correlations between NPI scores and SUVRs (results not shown). Discussion and Conclusions Our in vivo imaging of the amyloid plaque burden in the brains of people with mild AD suggests that having more plaques in specific brain regions, when estimated with SUVs, is associated with greater magnitude of disturbance in particular behaviours. However, SUVRs, which are ratios of region of interest to reference region (cerebellum), do not correlate with particular behaviours. This may be due to increased non-specific binding in the cerebellum, or perhaps these correlations truly do not exist. This will be clearer when the binding potentials are calculated. Overall, the existence of a plaque-behaviour relationship is unsupported by autopsy studies, and if we show that this relationship exists in living mild AD patients, this may suggest that amyloid pathology (i.e. plaques) may be associated with changes in behaviour in the earlier stages of dementia but not the later stages. Amyloid plaques are already widespread in mild AD; therefore, other pathologies, such as neurofibrillary tangles, synapse loss and neuronal death, may drive neuropsychiatric symptomatology in the moderate to severe stages of the disease. Our findings may be used to: (1) predict future behaviours in AD (2) enhance our understanding of brain-behaviour relationships in AD (3) lead to improved methods of managing behaviours associated with AD by improving drug treatment or caregiver education. Abbreviations: NPI, Neuropsychiatric Inventory; SUV, Standardized Uptake Value; OFC, orbitofrontal cortex; DLPFC, dorsolateral prefrontal cortex. * p < Results Summed PET images of a 49 year-old mild AD male 0-90 min after intravenous injection of the beta-amyloid plaque- specific radioligand [ 11 C]SB-13. Figure 3. Uptake of [ 11 C]SB-13 in the brain indicating location and density of amyloid plaques. Images captured via Positron Emission Tomography. SABRE regions of interest on MRI and PET image of a 49 year- old mild AD male. Figure 2. Left: Slice from MRI, with regions of interest traced. Right: Traced MRI image co-registered to PET image. NPI scores are calculated as products of frequency (1-4) and severity (1-3), for a maximum score of 12. Figure 1. Frequency distribution of the 12 NPI items.